Journal
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volume 7, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s40425-019-0749-z
Keywords
Immunotherapy; Hepatocellular carcinoma; Checkpoint blockade; Liver cancer; Immunology; Fibrosis
Categories
Funding
- NIAID NIH HHS [T32 AI007334] Funding Source: Medline
Ask authors/readers for more resources
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses from immune checkpoint inhibition in subsets of HCC patients across disease etiologies. The majority of HCC arises in the context of chronic inflammation and from within a fibrotic liver, with many cases associated with hepatitis virus infections, toxins, and fatty liver disease. Many patients also have concomitant cirrhosis which is associated with both local and systemic immune deficiency. Furthermore, the liver is an immunologic organ in itself, which may enhance or suppress the immune response to cancer arising within it. Here, we explore the immunobiology of the liver from its native state to chronic inflammation, fibrosis, cirrhosis and then to cancer, and summarize how this unique microenvironment may affect the response to immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available